Cholestatic Liver Diseases: New Strategies for Prevention and Treatment of Hepatobiliary and Cholestatic Liver

Cholestatic Liver Diseases: New Strategies for Prevention and Treatment of Hepatobiliary and Cholestatic Liver

List price: US$159.00

Currently unavailable

We can notify you when this item is back in stock

Add to wishlist

AbeBooks may have this title (opens in new window).

Try AbeBooks


The liver is the central organ in the metabolism and detoxification of many endogenous compounds. Recent studies have led to a better understanding of the pathways of uptake, transport, conjugation and biliary excretion of metabolites.
This book, the proceedings of the 75th Falk Symposium held in Maastricht, The Netherlands, presents progress in basic science in this field and the direct application of this knowledge to treatment of hepatobiliary diseases, such as primary biliary cirrhosis, primary sclerosing cholangitis and gallstone disease.
This book provides both research scientists and clinicians with all the information on cholestatic and hepatobiliary disease currently available.
show more

Product details

  • Hardback | 352 pages
  • 165.1 x 241.3 x 19.05mm | 767g
  • Dordrecht, Netherlands
  • English
  • 1995 ed.
  • 352 p.
  • 0792388674
  • 9780792388678

Table of contents

Preface. Section I: Mechanisms of Bile Formation and Cholestasis. 1. Histopathology of cholestasis; W.J. Desmet. 2. Mechanisms of bile formation; J.L. Boyer. 3. The enterohepatic circulation of bile acids in mammals; A.F. Hofmann. 4. The relationship between hepatobiliary transport and cholestatic properties of lithocholic acid conjugates in rats; F. Kuipers, R. Havinga, R. van der Meer, N.R. Koopen, R.J. Vonk. 5. Profiles of steroids and bile acids in plasma of patients with intrahepatic cholestasis of pregnancy -- effect of ursodeoxycholic acid therapy; L.J. Meng, H. Reyes, J. Palma, I. Hernandez, J. Ribalta, J. Sjoevall. Section II: Hepatocellular Transport and Mechanisms of Cholestasis. 6. Bilirubin metabolism in cholestasis; N. Blanckaert. 7. Molecular mechanisms of bile acid transport in hepatocytes; P.J. Meier. 8. Pathways of bile acid conjugation; S. Matern, H.-U. Marschall, H. Heinemann, C. Gartung, H. Wietholtz, H. Matern, J. Sjoevall. 9. Characterization of the mechanism of glucuronidation using photoaffinity labelling; A. Radominska, R.R. Drake, S. Treat, R. Lester. 10. Drugs, chemicals and cellular mechanisms of cholestasis; I.M. Arias, Z. Gatmaitan, J.F. Dufour, M. St.Pierre, L. Epstein, M. Che, Y. Matsuda, C. Leveille-Webster. 11. Transport of taurine conjugates of 7alpha-hydroxy-3-oxo-4-cholenoic acid and 3beta, 7alpha-dihydroxy-5-cholenoic acid in rat liver plasma membrane vesicles; B. Steiger, J. Zhang, B. O'Neill, J. Sjovall, P.J. Meier. Section III: Mechanisms of Gallstone Formation and Cholestasis. 12. Biliary lipid secretion and cholesterol transport; M.C. Carey. 13. Control of biliary lipid secretion. Studies in the mdr2 P-glycoprotein knock-out mouse; A.K. Groen, R. Ottendorf, M.J.A. van Wijland, J.J.M. Smit, A.H. Schinkel, R.P.J. Oude Elferink. 14. The role of gallbladder motility in the pathogenesis of cholesterol gallstones; M.F.J. Stolk, P. Portincasa, K.J. van Erpecum, G.P. van Berge Henegouwen. 15. Cholesterol crystal morphology is changed by a unique subgroup of lectin bound biliary proteins; N. Busch, F. Lammert, S. Matern. 16. Cholesterol crystal nucleation in bile: role of protein hydrophobicity; H.A. Ahmed, M.L. Petroni, M. Abu-Hamdiyyah, R.P. Jazraw, T.C. Northfield. 17. Nutrition associated cholestasis; P.B. Soeters. 18. Cholestatic liver diseases in children; C. Colombo. 19. Inborn errors of bile acid synthesis: a new category of metabolic liver disease; K.D.R. Setchell. Section IV: Ductopenic Diseases: Pathophysiology and Treatment. 20. Pathology of ductopenia with a particular reference to primary biliary cirrhosis and liver allograft rejection; B.C. Portmann. 21. Immunological aspects of cholestatic liver disease; M.F. Bassendine, D.E.J. Jones, M.P. Leon, J. Kiby, J.M. Palmer, S.J. Yeaman, A.G. Diamond. 22. Epidemiological and clinical features of primary biliary cirrhosis and primary sclerosing cholangitis; R.H. Wiesner. 23. Mechanisms of action of ursodeoxycholic acid in cholestasis; R. Poupon, R.E. Poupon. 24. Cytoprotection by ursodeoxycholic acid; U. Leuschner, S. Guldutuna, S. Bhatti, P. Sipos, T. You, G. Zimmer. 25. Methionine enkephalin and aminopeptidase-M activity in blood in children with cholestasis before and after treatment with ursodeoxycholic acid; R.M. Janas, J. Tretter, K. Warnawin, J. Pawlowska, J. Rujner, J. Socha. 26. Treatment with ursodeoxycholic acid, as monotherapy and in combination with other agents, in primary biliary cirrhosis; H.R. van Buuren, F.H.J. Wolfhagen, S.W. Schalm. 27. Methotrexate alone or in combination with ursodeoxycholic acid as possible treatment in primary biliary cirrhosis; W. Van Steenbergen, R. Sciot, P. Van Eycken, V. Desmet, J. Fevery. 28. Colchicine treatment and prognostic value of cholangiography in primary sclerosing cholangitis; R. Olsson, U. Broome, A. Danielsson, I. Hagerstrand, G. Jarnerot, L. Loof, H. Prytz, B.-O. Ryden, S. Wallerstedt, M. Asztely. 29. Treatment of primary sclerosing cholangitis; R.W. Chapman. 30. Treatment of primary sclerosing cholangitis with ursodeoxycholic acid; A. Stiehl. 31. Liver transplantation for cholestatic liver diseases; J.B. Otte, J. Lerut. 32. Large bile duct strictures in primary sclerosing cholangitis patients developing ductopenic rejection after liver transplantation; does this represent ...; B. van Hoek, R.H. Wiesner, L. Sanchez-Urdazpal, J. Ludwig, R.A.F. Krom. Section V: Gallbladder and Bile Duct Stone: Epidemiology and Treatment. 33. Epidemiology of gallstone disease; E. Road, D. Festi, S. Sottili, A. Sangermano, A. Colecchia, M. Orsini, the MICOL Group. 34. Duodenal diverticula are associated with pancreatic, biliary and intestinal anomalies; J.P. van Basten, P. Caenepeel, R. Zeijen, R.W. Stockbrugger.
show more